🇺🇸 FDA

Intelligence · Clinical Pipeline

George Institute for Pipeline

All ClinicalTrials.gov programs at George Institute for — phase, modality, and trial IDs.

Programs
406

Quick answer

George Institute for has 406 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment

    The George Institute

    Newly diagnosed and/or previously treated IDH1-mutated malignancies

    phase 1 other active

    1 trial

  2. A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer´s disease.

    The George Institute

    Alzheimer´s disease

    phase 1 other active

    1 trial

  3. A randomised, assessor-blinded, controlled, healthy volunteer, Phase I study to assess skin irritation and sensitization potential of a novel 5% lidocaine medicated plaster

    The George Institute

    None. Healthy subjects

    phase 1 other active

    1 trial

  4. A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer

    The George Institute

    Refractory metastatic Her2 positive breast cancer

    phase 1 other active

    1 trial

  5. A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT

    The George Institute

    Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors

    phase 1 other active

    1 trial

  6. A study to find out how healthy people tolerate a new drug called S221237.

    The George Institute

    Parkinson disease (PD)

    phase 1 other active

    1 trial

  7. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

  8. Autologous tolerogenic dendritic cells (ATDC) for highly sensitized kidney transplant recipients

    The George Institute

    Kidney trasplants

    phase 1 other active

    1 trial

  9. Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fasting Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  10. Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  11. Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  12. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  13. CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

    The George Institute

    Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  14. CD5CAR-NK cells for refractory invasive mold disease

    The George Institute

    refractory invasive mold disease

    phase 1 other active

    1 trial

  15. CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

    The George Institute

    Acute leukemia and myelodysplastic syndromes

    phase 1 other active

    1 trial

  16. CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

    The George Institute

    Patients with recurrent and/or metastatic solid cancer.

    phase 1 other active

    1 trial

  17. Comparative Pharmacokinetic of S221237 Tablets in Healthy Participants Under Fed Conditions

    The George Institute

    No medical condition

    phase 1 other active

    1 trial

  18. Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (High Fat High Calorie Meal and Standard Meal).

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  19. First in human pilot study to assess the safety and efficacy of dendritic cells loaded with frameshift derived neopeptides for the prevention of cancer in Lynch Syndrome carriers

    The George Institute

    Lynch Syndrome

    phase 1 other active

    1 trial

  20. First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma

    The George Institute

    Relapsed/refractory B-cell aggressive lymphoma

    phase 1 other active

    1 trial

  21. M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors

    The George Institute

    Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.

    phase 1 other active

    1 trial

  22. Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  23. Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.

    The George Institute

    No medical condicion.

    phase 1 other active

    1 trial

  24. NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

    The George Institute

    resectable esophagogastric adenocarcinoma

    phase 1 other active

    1 trial

  25. Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

    The George Institute

    Non-small cell lung cancer (NSCLC)

    phase 1 other active

    1 trial

  26. Phase I single-blind clinical trial to evaluate the safety and local immune activation of a toll-like receptor 5 agonist (FLAMOD) administered by aerosol

    The George Institute

    Pneumonia

    phase 1 other active

    1 trial

  27. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  28. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  29. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  30. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  31. Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  32. Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.

    The George Institute

    Idiopathic Pulmonary Fibrosis

    phase 1 other active

    1 trial

  33. Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

    The George Institute

    advanced or metastasic triple-negative breast cancer

    phase 1 other active

    1 trial

  34. clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee

    The George Institute

    Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments

    phase 1 other active

    1 trial

  35. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  36. -

    The George Institute

    Acute lower Respiratory Tract Infection or acute rhinosinusitis

    approved small molecule active

    1 trial

  37. ACETYLSALICYLIC ACID

    The George Institute

    Obstetrics – Preeclampsia

    approved small molecule active

    1 trial

  38. ALUTARD SQ epitel, injektionsvätska, suspension - 553 Hund, Livostin 0,5 mg/ml ögondroppar, suspension, Desloratadine Sandoz 5 mg filmdragerade tabletter, Nasonex 50 mikrogram/dos nässpray, suspension

    The George Institute

    Allergic rhinitis due to dog allergy

    approved small molecule active

    1 trial

  39. AMOXICILINA NORMON 1000 mg Comprimidos EFG

    The George Institute

    Infective endocarditis

    approved small molecule active

    1 trial

  40. ASS-ratiopharm® 100 mg TAH Tabletten, Xarelto 15 mg film-coated tablets

    The George Institute

    Risk of stroke by Atrial Fibrillation

    approved small molecule active

    1 trial

  41. Adrenalina B. Braun 1 mg/ml Solución Inyectable, Ropivacaína B. Braun 2 mg/ml solución inyectable y para perfusión EFG

    The George Institute

    Knee Osteoarthritis

    approved small molecule active

    1 trial

  42. Alirocumab, Placebo product for REGN727

    The George Institute

    Cardiac allograft vaculopathy in recent heart transplant recipients

    approved small molecule active

    1 trial

  43. Amiodarone hydrochloride 200 mg tablets

    The George Institute

    Persistent atrial fibrillation

    approved small molecule active

    1 trial

  44. Amoxicilina/Ácido clavulánico NORMON 1.000 mg/200 mg polvo para solución inyectable y para perfusión EFG, Amoxicilina/Ácido clavulánico NORMON 875 mg/125 mg comprimidos recubiertos con película EFG

    The George Institute

    Complicated acute appendicitis

    approved small molecule active

    1 trial

  45. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted), Spikevax bivalent Original/Omicron BA.1 25 micrograms/25 micrograms dispersion for injection COVID 19 mRNA Vaccine, Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Nuvaxovid dispersion for injection COVI

    The George Institute

    COVID-19 infection

    approved small molecule active

    1 trial

  46. BUDESONIDE

    The George Institute

    Chronic obstructive pulmonary disease (COPD)

    approved small molecule active

    1 trial

  47. Betadine bucal 100 mg/ml solución bucal, Agua oxigenada Foret 3 % solución cutánea y concentrado para solución bucal, Agua para preparaciones inyectables Meinsol, disolvente para uso parenteral

    The George Institute

    Respiratory diseases

    approved small molecule active

    1 trial

  48. CARDIOPLEGIA SOLUTIONS

    The George Institute

    Cardiovascular pathology

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does George Institute for have?

406 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.